INZY
Inozyme Pharma
INZY
INZY
Delisted
INZY was delisted on the 30th of June, 2025.
49 hedge funds and large institutions have $183M invested in Inozyme Pharma in 2023 Q1 according to their latest regulatory filings, with 17 funds opening new positions, 18 increasing their positions, 5 reducing their positions, and 5 closing their positions.
New
Increased
Maintained
Reduced
Closed
more capital invested
Capital invested by funds: $ → $
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
more first-time investments, than exits
New positions opened: | Existing positions closed:
more funds holding in top 10
Funds holding in top 10: →
32% more funds holding
Funds holding: 37 → 49 (+12)
1.5% more ownership
Funds ownership: 71.66% → 73.16% (+1.5%)
56% less call options, than puts
Call options by funds: $166K | Put options by funds: $378K
Holders
49
Holding in Top 10
2
Calls
$166K
Puts
$378K
Top Buyers
| 1 | +$7.98M | |
| 2 | +$6.68M | |
| 3 | +$4.55M | |
| 4 |
Fidelity Investments
Boston,
Massachusetts
|
+$4.03M |
| 5 |
PBPIA
Pivotal bioVenture Partners Investment Advisor
San Francisco,
California
|
+$3.17M |
Top Sellers
| 1 | -$4.94M | |
| 2 | -$2.85M | |
| 3 | -$417K | |
| 4 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
-$91.7K |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
-$87.9K |